Testing the addition of a new anti-cancer drug, radium-223 dichloride, to the usual treatment (cabozantinib) for advanced renal cell cancer that has spread to the bone

This study is being done to answer the following question: Can we lessen the pain you have and improve the way you live with cancer that has spread to the bone by adding a new drug to the usual drug given? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your advanced renal cell cancer. The usual approach is defined as care most people get for advanced renal cell cancer.